21 active not recruiting. 21 Phase 2, 7 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Active not recruiting 21 |
| Phase 1 | 7 | Active not recruiting 7 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fecal Microbiota Transplantation for Steroid-resistant or Relapsed Immune Thrombocytopenia Fecal microbiota transplantation - Immune Thrombocytopenia (ITP) | Phase 2 | Active not recruiting | Peking University People's Hospital | 42 | 2026-01-10 | 2026-07-29 |
| Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A Switching to low dose emicizumab - Hemophilia A Patient | Phase 2 / Phase 3 | Active not recruiting | Chulalongkorn University | 18 | 2025-06-01 | 2026-02-27 |
| Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) CM313 injection, placebo - Primary Immune Thrombocytopenia | Phase 2 | Active not recruiting | Keymed Biosciences Co.Ltd | 62 | 2024-11-11 | 2025-04-23 |
| A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia CM313 Injection, Placebo Injection - Immune Thrombocytopenia, Treatment | Phase 2 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 45 | 2024-01-16 | 2024-12-30 |
| A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies Ianalumab - Primary Immune Thrombocytopenia (ITP) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 41 | 2023-08-16 | 2026-10-20 |
| A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A ANB-010, dose 1, ANB-010, dose 2, ANB-010, dose 3 - Hemophilia A | Phase 1 / Phase 2 | Active not recruiting | Biocad | 50 | 2023-07-26 | 2025-04-24 |
| To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A GS1191-0445 injection - Severe Hemophilia A | Phase 1 / Phase 2 | Active not recruiting | Gritgen Therapeutics Co., Ltd. | 7 | 2023-07-10 | 2026-05-06 |
| A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia HMB-001 - Glanzmann Thrombasthenia | Phase 1 / Phase 2 | Active not recruiting | Hemab ApS | 57 | 2022-12-13 | 2026-09-25 |
| A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET Ropeginterferon alfa-2b-njft (P1101) - Essential Thrombocythemia | Phase 2 | Active not recruiting | PharmaEssentia | 91 | 2022-09-29 | 2025-08-13 |
| Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug Single dose intravenous injection of BBM-H901 - Hemophilia B | Phase 2 / Phase 3 | Active not recruiting | Shanghai Xinzhi BioMed Co., Ltd. | 32 | 2021-12-30 | 2026-04-01 |
| A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP dexamethasone, diammonium glycyrrhizinate enteric-coated capsule - Immune Thrombocytopenia | Phase 2 | Active not recruiting | Shandong University | 106 | 2021-08-21 | 2026-01-26 |
| IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) IMG-7289 - Essential Thrombocythemia, Polycythemia Vera | Phase 2 | Active not recruiting | Terrence J Bradley, MD | 4 | 2020-10-02 | 2026-01-07 |
| Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 IMG-7289 - Thrombocythemia, Essential | Phase 2 | Active not recruiting | The University of Texas Health Science Center at San Antonio | 9 | 2020-04-09 | 2026-10-22 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Pevonedistat, Venetoclax - Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 40 | 2019-02-27 | 2026-07-16 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Carboplatin, Topotecan, Topotecan Hydrochloride - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 25 | 2018-09-24 | 2026-06-23 |
| Gene Therapy for Haemophilia A. AAV2/8-HLP-FVIII-V3 - Hemophilia A | Phase 1 / Phase 2 | Active not recruiting | University College, London | 14 | 2017-06-14 | 2025-03-05 |
| The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Ruxolitinib, BAT - Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Active not recruiting | RWTH Aachen University | 207 | 2015-10-01 | 2026-08-13 |
| Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome Autologous CD34+ cells transduced with WASP lentiviral vector - Wiskott-Aldrich Syndrome | Phase 1 / Phase 2 | Active not recruiting | Genethon | 10 | 2014-09-01 | 2021-06-03 |
| Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms givinostat - Chronic Myeloproliferative Neoplasms | Phase 2 | Active not recruiting | Italfarmaco | 90 | 2013-03-01 | 2025-04-30 |
| Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B AskBio009 - Hemophilia B | Phase 1 / Phase 2 | Active not recruiting | Baxalta now part of Shire | 30 | 2013-02-11 | 2026-03-20 |
Showing 20 of 21. Sign in to see all of them.
Thrombocythemia, Essential (8) · Polycythemia Vera (6) · Purpura, Thrombocytopenic, Idiopathic (5) · Hemophilia A (4) · Myeloproliferative Disorders (4) · Primary Myelofibrosis (4) · Leukemia, Myeloid, Acute (3) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (3) · Leukemia, Myelomonocytic, Chronic (3) · Hemophilia B (2) · Leukemia, Neutrophilic, Chronic (2) · Myelodysplastic Syndromes (2) · Myelodysplastic-Myeloproliferative Diseases (2) · Thrombocytosis (2) · Anemia, Aplastic (1)
Hematologic Diseases (21) · Hemic and Lymphatic Diseases (21) · Hemorrhagic Disorders (21) · Blood Platelet Disorders (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Blood Coagulation Disorders, Inherited (8) · Bone Marrow Diseases (8) · Genetic Diseases, Inborn (8) · Immune System Diseases (7) · Bone Marrow Neoplasms (6) · Coagulation Protein Disorders (6) · Cytopenia (6)
bomedemstat (2) · Azacitidine (1) · BAX 335 (1) · Busulfan (1) · Carboplatin (1) · Cyclophosphamide (1) · Cyclosporine (1) · Dexamethasone (1) · Drug Evaluation (1) · Etoposide (1) · Fecal Microbiota Transplantation (1) · Melphalan (1) · Methotrexate (1) · Mycophenolic Acid (1) · Peripheral Blood Stem Cell Transplantation (1)
Baxalta now part of Shire (1) · Biocad (1) · Chulalongkorn University (1) · City of Hope Medical Center (1) · Genethon (1) · Gritgen Therapeutics Co., Ltd. (1) · Hemab ApS (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Italfarmaco (1) · Keymed Biosciences Co.Ltd (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1) · Peking University People's Hospital (1) · PharmaEssentia (1)
United States (9) · China (7) · United Kingdom (5) · France (3) · Germany (3) · Italy (3) · Argentina (1) · Australia (1) · Belgium (1) · Canada (1) · Malaysia (1) · Netherlands (1) · Poland (1) · Russia (1) · South Korea (1)
Lei Zhang, MD (2) · Alessandro Rambaldi, MD (1) · Arina V Zinkina-Orikhan, PhD (1) · Auayporn P. Nademanee, MD (1) · Caifeng Yang, Master (1) · Keith W Pratz (1) · Lei Zhang (1) · Ming Hou, MD,PhD (1) · Nicholas Short (1) · Oleh Zagrijtschuk, MD, PhD (1) · Pratima Chowdary, MD (1) · Steffen Koschmieder, Prof. Dr. (1) · Terrence J Bradley, MD (1)
PMID 30003118, PMID 33067633, PMID 33609248, PMID 35075289, PMID 36564535, PMID 37422688, PMID 37592092, PMID 40330782, PMID 40441148, PMID 41120215, PMID 41180128, PMID 41266685, PMID 42178778, PMID 42306077
2016 (1), P30CA033572 (1), UM1CA186691 (1)